Aktis Oncology, Inc. (AKTS) stock
AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.31+0.15 (+0.93%)
Close on Nov 17, 2026Market cap $907.15MP/E –Yield –
Aktis Oncology operating margin
Operating margin is operating income as a percentage of revenue.
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -889.8% | +419.6 |
| Q2 FY2026 | Jun 30, 2026 | -854.0% | +399.8 |
| Q1 FY2026 | Mar 31, 2026 | -703.6% | – |
| Q3 FY2025 | Sep 30, 2025 | -1152.8% | – |
| Q2 FY2025 | Jun 30, 2025 | -1309.4% | – |
| Q1 FY2025 | Mar 31, 2025 | -1253.8% | – |
See a number that looks wrong?